99 related articles for article (PubMed ID: 7797410)
1. Magnetization transfer and high-dose contrast in early brain infection on magnetic resonance.
Runge VM; Wells JW; Kirsch JE
Invest Radiol; 1995 Mar; 30(3):135-43. PubMed ID: 7797410
[TBL] [Abstract][Full Text] [Related]
2. Detectability of early brain meningitis with magnetic resonance imaging.
Runge VM; Wells JW; Williams NM; Lee C; Timoney JF; Young AB
Invest Radiol; 1995 Aug; 30(8):484-95. PubMed ID: 8557515
[TBL] [Abstract][Full Text] [Related]
3. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
[TBL] [Abstract][Full Text] [Related]
4. Detectability of small liver metastases with gadolinium BOPTA.
Runge VM; Lee C; Williams NM
Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
[TBL] [Abstract][Full Text] [Related]
5. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1995 Feb; 30(2):123-30. PubMed ID: 7782188
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of standard and high-dose contrast-enhanced breath-hold liver magnetic resonance for visualization of metastatic disease in an animal model.
Runge VM
Invest Radiol; 1998 May; 33(5):263-7. PubMed ID: 9609484
[TBL] [Abstract][Full Text] [Related]
7. Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Aug; 31(8):472-8. PubMed ID: 8854193
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
[TBL] [Abstract][Full Text] [Related]
9. The use of gadolinium-BOPTA on magnetic resonance imaging in brain infection.
Runge VM; Wells JW; Williams NM; Timoney JF; Lee C
Invest Radiol; 1996 May; 31(5):294-9. PubMed ID: 8724129
[TBL] [Abstract][Full Text] [Related]
10. [Brain magnetic resonance with magnetization transfer in multiple sclerosis. Lesion hyperintensity before and after intravenous gadolinium administration].
Renzetti P; Parodi RC; Losacco C; Rosso E; Arcuri T; Sardanelli F
Radiol Med; 1999 Sep; 98(3):138-43. PubMed ID: 10575442
[TBL] [Abstract][Full Text] [Related]
11. Gadoteridol in multiple sclerosis patients. A comparison of single and triple dose with immediate vs. delayed imaging.
Wolansky LJ; Finden SG; Chang R; Conigliari M; Lee HJ; Shaderowsky PD; Cook SD
Clin Imaging; 1998; 22(6):385-92. PubMed ID: 9876905
[TBL] [Abstract][Full Text] [Related]
12. Contrast-enhanced magnetic resonance imaging in a spinal epidural tumor model.
Runge VM; Lee C; Iten AL; Williams NM
Invest Radiol; 1997 Oct; 32(10):589-95. PubMed ID: 9342117
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1994 Dec; 29(12):1050-6. PubMed ID: 7721546
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
[TBL] [Abstract][Full Text] [Related]
15. Renal metastasis. Detection and characterization on enhanced magnetic resonance imaging using an animal model.
Runge VM; Wells JW; Williams NM
Invest Radiol; 1997 Apr; 32(4):212-7. PubMed ID: 9101356
[TBL] [Abstract][Full Text] [Related]
16. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material.
Runge VM; Kirsch JE; Wells JW; Dunworth JN; Woolfolk CE
AJR Am J Roentgenol; 1994 Feb; 162(2):431-5. PubMed ID: 8310940
[TBL] [Abstract][Full Text] [Related]
17. Cerebral infarction: effects of dose and magnetization transfer saturation at gadolinium-enhanced MR imaging.
Mathews VP; King JC; Elster AD; Hamilton CA
Radiology; 1994 Feb; 190(2):547-52. PubMed ID: 8284414
[TBL] [Abstract][Full Text] [Related]
18. Gadoteridol dose dependence in MR imaging of a liver abscess model.
Runge VM; Kirsch JE; Woolfolk C; Brack MA; Garneau RA
J Magn Reson Imaging; 1994; 4(3):343-50. PubMed ID: 8061432
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging of experimental pyelonephritis in rabbits.
Runge VM; Timoney JF; Williams NM
Invest Radiol; 1997 Nov; 32(11):696-704. PubMed ID: 9387058
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
Carvlin MJ; De Simone DN; Meeks MJ
Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
